Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Replimune Group (NASDAQ:REPL) released its earnings results on Monday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10), FiscalAI reports.

Replimune Group Price Performance

Shares of REPL stock opened at $11.20 on Tuesday. The firm has a market cap of $924.78 million, a P/E ratio of -3.26 and a beta of 0.88. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.24. The business’s 50 day moving average price is $6.41 and its 200-day moving average price is $7.29. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Analyst Upgrades and Downgrades

REPL has been the topic of several recent research reports. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. BMO Capital Markets cut shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price objective on the stock in a report on Friday. Finally, Piper Sandler lowered Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, April 10th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Replimune Group presently has an average rating of “Reduce” and a consensus price target of $6.00.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of REPL. Invesco Ltd. increased its position in shares of Replimune Group by 297.3% during the fourth quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock valued at $5,959,000 after buying an additional 458,714 shares during the period. XTX Topco Ltd purchased a new position in shares of Replimune Group during the 4th quarter worth approximately $322,000. Virtus Investment Advisers LLC grew its holdings in shares of Replimune Group by 127.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock worth $254,000 after acquiring an additional 14,622 shares during the period. SummitTX Capital L.P. bought a new position in shares of Replimune Group in the 4th quarter worth approximately $1,058,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in shares of Replimune Group in the 4th quarter valued at approximately $650,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.